1-(2-氨基苯基)-4-哌啶醇 | 252758-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(2-氨基苯基)-4-哌啶醇
• 英文名称: 1-(2-aminophenyl)piperidin-4-ol
• CAS: 252758-96-6
• 化学式: C₁₁H₁₆N₂O
• mdl: MFCD09734091
• 分子量: 192.261
• InChiKey: KHXSBUSJNPXVGY-UHFFFAOYSA-N

物化性质

• 沸点：
  369.8±37.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  49.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1-(2-氨基苯基)-4-哌啶醇 、 5-硝基-2-糠酰氯 在 PS-morpholine 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 5-nitro-furan-2-carboxylic acid [2-(4-hydroxy-piperidin-1-yl)-phenyl]-amide
  参考文献：
  名称：

  Potent 2′-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents

  摘要：

  A series of 2 '-aminoanilides have been identified which exhibit potent and selective inhibitory activity against the cFMS tyrosine kinase. Initial SAR studies within this series are described which examine aroyl and amino group substitutions, as well as the introduction of hydrophilic substituents on the benzene core. Compound 47 inhibits the isolated enzyme (IC50 = 0.027 mu M) and blocks CSF-1-induced proliferation of bone marrow-derived macrophages (IC50 = 0.11 mu M) and as such, serves as a lead candidate for further optimization studies. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.057
• 作为产物：
  描述：

  1-(2-Nitrophenyl)piperidine-4-ol 在 palladium on activated charcoal 氢气 、 溶剂黄146 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 生成 1-(2-氨基苯基)-4-哌啶醇
  参考文献：
  名称：

  Potent 2′-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents

  摘要：

  A series of 2 '-aminoanilides have been identified which exhibit potent and selective inhibitory activity against the cFMS tyrosine kinase. Initial SAR studies within this series are described which examine aroyl and amino group substitutions, as well as the introduction of hydrophilic substituents on the benzene core. Compound 47 inhibits the isolated enzyme (IC50 = 0.027 mu M) and blocks CSF-1-induced proliferation of bone marrow-derived macrophages (IC50 = 0.11 mu M) and as such, serves as a lead candidate for further optimization studies. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.057

文献信息

• [EN] SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF<br/>[FR] PETITES MOLÉCULES AGONISTES DE LA MUCOLIPINE 1 ET LEURS UTILISATIONS
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2021041866A1

  公开（公告）日：2021-03-04

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.

  这项发明属于药物化学领域。特别是，该发明涉及一类新的小分子，具有苯磺酰胺（或类似）结构，作为肌球脂蛋白1（ML1）的激动剂，以及它们作为治疗杜氏肌肉萎缩症（DMD）和相关疾病的疗法的用途。
• C-fms kinase inhibitors
  申请人：Player R. Mark

  公开号：US20050004112A1

  公开（公告）日：2005-01-06

  The invention is directed to compounds of Formulae I, II and III: wherein A, R 1 , R 2 , R 3 , R 4 , X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

  本发明涉及式I、II和III的化合物：其中A、R1、R2、R3、R4、X、Y和W在说明书中列出，以及其溶剂化物、水合物、互变异构体或药学上可接受的盐，其抑制蛋白酪氨酸激酶，特别是c-fms激酶。
• Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings
  申请人：Hutchinson K. Douglas

  公开号：US20050054683A1

  公开（公告）日：2005-03-10

  A process for preparing a compound of the formula I: or pharmaceutical acceptable salts thereof wherein X is —NR 1 —, —S(O) g —, or —O—; R 1 is —H, C 1-6 alkyl optionally substituted with one or more —OH, —CN, or halo, or R 1 is —(CH 2 ) h -aryl, —COR 1-1 , —COOR 1-2 , —CO—(CH 2 ) h —COR 1-1 , C 1-6 alkyl sulfonyl, —SO 2 —(CH 2 ) h -aryl, or —(CO) i -Het; R 2 is —H, C 1-6 alkyl, —(CH 2 ) h -aryl, or halo; R 3 and R 4 are the same or different and are —H or halo; R 5 is —H, C 1-12 alkyl optionally substituted with one or more halo, C 3-12 cycloalkyl, C 1-6 alkoxy. The compounds are useful antimicrobial agents.

  一种制备公式I化合物或其药学可接受的盐的方法，其中X为—NR1—，—S（O）g—或—O—; R1为—H，C1-6烷基，可选地取代一个或多个—OH，—CN或卤素，或R1为—（CH2）h-芳基，—COR1-1，—COOR1-2，—CO—（ ）h—COR1-1，C1-6烷基磺酰基，—SO2—（ ）h-芳基或—（CO）i-Het; R2为—H，C1-6烷基，—（ ）h-芳基或卤素; R3和R4相同或不同，为—H或卤素; R5为—H，C1-12烷基，可选地取代一个或多个卤素，C3-12环烷基，C1-6烷氧基。这些化合物是有用的抗微生物药物。
• c-fms kinase inhibitors
  申请人：Player R. Mark

  公开号：US20060258666A1

  公开（公告）日：2006-11-16

  The invention is directed to compounds of Formula II: wherein A, R 1 , R 2 , R 3 , R 4 , X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

  本发明涉及公式II的化合物： 其中A、R1、R2、R3、R4、X、Y和W在说明书中有所阐述，以及其溶剂化物、水合物、互变异构体或药学上可接受的盐，其可抑制蛋白酪氨酸激酶，特别是c-fms激酶。
• Thienopyrazole Derivative Having PDE7 Inhibitory Activity
  申请人：Inoue Hidekazu

  公开号：US20090131413A1

  公开（公告）日：2009-05-21

  To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: —CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].

  为了提供选择性抑制PDE 7的噻唑吡啶衍生物，从而增强细胞cAMP水平。因此，该化合物可用于治疗各种疾病，如过敏性疾病、炎症性疾病或免疫性疾病。该化合物是由以下式子(I)表示的噻唑吡啶化合物：[其中，特别地，R1是环己基、环庚基或四氢吡喃基；R2是甲基；R3是氢原子；R4是一个基团：—CONR5R6（其中R5和R6中的任何一个是氢原子）]。